CTOs on the Move

Point32Health

www.point32health.org

 
The combination of Tufts Health Plan and Harvard Pilgrim Health Care represents the coming together of two of New England`s most iconic nonprofit health care companies. Representing nearly 90 years of combined service to our members and the community, together we are building upon our diverse legacies and innovative collaboration by making it our purpose to guide and empower healthier lives for everyone — no matter their age, health, race, identity, or income. That`s why we`ve named our new corporate entity Point32Health. The Point32Health name is inspired by the 32 points on a compass. It speaks to the critical role we ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Keith Wilson
 Manager, Cyber and Information Security - Threat Management Profile
Tony Faria
 Chief Information Security Officer Profile

Similar Companies

Allphase Clinical Research Services

Allphase Clinical Research Services Inc. is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hilsinger Company dba Hilco USA

Hilsinger Company L.P. dba Hilco USA is a Plainville, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Information Technology, Inc.

Medical Information Technology, Inc. (MEDITECH) is engaged in developing, manufacturing and marketing of computer software products for the hospital industry. The wholly owned subsidiary of the Company is Patient Care Technologies, Inc. (PtCT).

The Community Health Network of Connecticut Foundation

The Community Health Network of Connecticut Foundation is a Wallingford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fibrocell Science

Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.